Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asundexian (Primary) ; Apixaban
Indications Thromboembolism
Focus Adverse reactions
Acronyms PACIFIC-AF
Sponsors Bayer

Most Recent Events

22 Aug 2022 According to Bayer media release, a joint session with ESC and The Lancet will review data from this trial.
22 Aug 2022 According to Bayer media release, data from this trial will be presented at the European Society of Cardiology's 70th Annual Scientific Session (ESC.22).
03 Apr 2022 According to Bayer media release, results from this trial published in the The Lancet.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight